Dare Bioscience is a biotechnology business based in the US. Dare Bioscience shares (DARE) are listed on the NASDAQ and all prices are listed in US Dollars. Dare Bioscience employs 23 staff and has a trailing 12-month revenue of around $2.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.69 |
|---|---|
| 52-week range | $3.05 - $9.48 |
| 50-day moving average | $4.62 |
| 200-day moving average | $4.62 |
| Wall St. target price | $48.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.96 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.69 from 2024-07-22
| 1 week (2024-07-17) | 6.03% |
|---|---|
| 1 month (2024-06-24) | 732.96% |
| 3 months (2024-04-24) | 1,190.21% |
| 6 months (2024-01-24) | 1,067.35% |
| 1 year (2023-07-24) | 385.53% |
|---|---|
| 2 years (2022-07-22) | 226.55% |
| 3 years (2021-07-23) | 147.65% |
| 5 years (2019-07-24) | 392.00% |
| Revenue TTM | $2.8 million |
|---|---|
| Gross profit TTM | $9.9 million |
| Return on assets TTM | -81.78% |
| Return on equity TTM | -994.69% |
| Profit margin | 0% |
| Book value | $-1.31 |
| Market Capitalization | $29.8 million |
TTM: trailing 12 months
We're not expecting Dare Bioscience to pay a dividend over the next 12 months.
Dare Bioscience's shares were split on a 1:12 basis on 30 June 2024. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Dare Bioscience shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Dare Bioscience shares which in turn could have impacted Dare Bioscience's share price.
Over the last 12 months, Dare Bioscience's shares have ranged in value from as little as $3.05 up to $9.4788. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dare Bioscience's is 1.373. This would suggest that Dare Bioscience's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Daré Bioscience, Inc. , a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.